Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients

Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients

Objective: Based on the TAX 327 Phase III trial, docetaxel (DTX)-based chemotherapy is the standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC). However, some heterogeneity is observed in clinical practice. The present study aimed to evaluate the outcomes of a we...

Full description

Bibliographic Details
Main Authors: Cheng-Li Kao, Tai-Lung Cha, Chien-Chang Kao, Chu-Wei Tsao, Shou-Hung Tang, En Meng, Guang-Haun Sun, Dah-Shyong Yu, Bo-Han Chen, Sheng-Tang Wu
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-12-01
Series:Urological Science
Subjects:
castration-resistant
docetaxel
prostate cancer
weekly
Online Access:http://www.sciencedirect.com/science/article/pii/S1879522615004169

Internet

http://www.sciencedirect.com/science/article/pii/S1879522615004169

Similar Items